Plooster Matthew R's Form 4 filing
Zevra Therapeutics, Inc. (ZVRA) · filed May 18, 2022
- Accession no.
- 0001437749-22-012945
- Filed
- May 18, 2022
- Trade date
- May 18, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $24.8K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Plooster Matthew RCIK 0001638364 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 18, 2022 | Common Stock | PPurchaseAcquired | +695 | $4.94 | +$3,433.3 | 3,195 | Direct | |
| May 18, 2022 | Common Stock | PPurchaseAcquired | +915 | $4.95 | +$4,529.25 | 4,110 | Direct | |
| May 18, 2022 | Common Stock | PPurchaseAcquired | +3,051 | $4.96 | +$15,132.96 | 7,161 | Direct | |
| May 18, 2022 | Common Stock | PPurchaseAcquired | +339 | $4.97 | +$1,684.83 | 7,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.